PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
19187276-3	2009	Rivaroxaban, an oral, once-daily, direct Factor Xa inhibitor, has recently completed the RECORD phase III programme for the prevention of VTE in patients undergoing total hip or knee replacement (THR or TKR), an indication for which it is approved in Europe and Canada.	Rivaroxaban	0-11	transketolase like 1	Homo sapiens	203-206	
19187276-6	2009	The four RECORD studies consistently showed that rivaroxaban was significantly more effective than enoxaparin in the prevention of VTE after THR and TKR, with a similar safety profile.	Rivaroxaban	49-60	transketolase like 1	Homo sapiens	149-152	
19185785-4	2008	Moreover, among the new oral anticoagulants, rivaroxaban has a better efficacy than enoxaparin to prevent thromboembolic events after major orthopaedic surgery (THR and TKR).	Rivaroxaban	45-56	transketolase like 1	Homo sapiens	169-172